التفاصيل البيبلوغرافية
| العنوان: |
Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma. |
| المؤلفون: |
Van Tine, Brian A, Weiss, Mia C, Hirbe, Angela C, Oppelt, Peter J, Abaricia, Sarah, Trinkaus, Kathryn, Luo, Jingqin, Berry, Shellie, Ruff, Tyler, Callahan, Cheryl, Toensikoetter, Jacqui, Ley, Jessica, Siegel, Marilyn J, Dehdashti, Farrokh, Siegel, Barry A, Adkins, Douglas R |
| المصدر: |
Rare Tumors; 10/8/2021, p1-9, 9p |
| مصطلحات موضوعية: |
OSTEOSARCOMA, DACARBAZINE, POSITRON emission tomography, OVERALL survival, SURVIVAL rate |
| مستخلص: |
Historically, administration of dacarbazine to sarcoma patients was limited by frequent treat-ment-related nausea/vomiting and neutropenia. These toxicities are now largely preventable with contemporary antiemetics and growth factor support. In this single-arm, phase II study, dacarbazine 850 mg/m2 was given on day 1 of each 3-week cycle until disease progression or intolerance with prophylactic serotonin-3 receptor, neurokinin-1 antagonists, corticosteroids, and pegfilgrastim. Coprimary endpoints included clinical benefit rate (CBR), and any grade of nausea/vomiting and/or grade 3–4 neutropenia. With a sample size of 80 patients, >24 patients with clinical benefit would indicate that the CBR exceeds the historical (<20%) [Power 0.80; alpha 0.05]. In addition, we hypothesized that the rates of nausea/vomiting would be 27% and grade 3–4 neutropenia would be 1% (historical: 90% and 36%, respectively) [power 0.95; alpha 0.05]. The CBR was 30% (24 patients: PR-2 and stable-22). The rate of nausea/vomiting was 37.5% (31 patients) and grades 3–4 neutropenia was 10% (8 patients). Median time-to-progression was 8.1 weeks (95% CI 8–9.7) and median overall survival was 35.8 weeks (95% CI 26.2–55.4). PET scans demonstrated no association with response. Modern prophylactic anti-emetics and pegfilgrastim given with dacarbazine reduced the rates of treatment related nausea/vomiting and serious neutropenia. [ABSTRACT FROM AUTHOR] |
|
Copyright of Rare Tumors is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder